Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Other Non Operating Income (2018 - 2025)

Adma Biologics' Other Non Operating Income history spans 8 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 31.01% year-over-year to $3.0 million; the TTM value through Dec 2025 reached -$406000.0, down 109.59%, while the annual FY2025 figure was $2.8 million, 35.51% down from the prior year.
  • Other Non Operating Income reached $3.0 million in Q4 2025 per ADMA's latest filing, up from -$2.2 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $4.3 million in Q4 2024 to a low of -$6.7 million in Q1 2022.
  • Average Other Non Operating Income over 5 years is -$181588.2, with a median of -$35000.0 recorded in 2024.
  • Peak YoY movement for Other Non Operating Income: tumbled 171086.44% in 2023, then soared 4397.03% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $106772.0 in 2021, then plummeted by 100.06% to -$59.0 in 2022, then crashed by 171086.44% to -$101000.0 in 2023, then skyrocketed by 4397.03% to $4.3 million in 2024, then crashed by 31.01% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Other Non Operating Income are $3.0 million (Q4 2025), -$2.2 million (Q3 2025), and -$1.2 million (Q2 2025).